A study to evaluate the total and regional pulmonary deposition of the fluticasone propionate/formoterol using two-dimensional gamma scintigraphy

Trial Profile

A study to evaluate the total and regional pulmonary deposition of the fluticasone propionate/formoterol using two-dimensional gamma scintigraphy

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Formoterol/fluticasone propionate (Primary)
  • Indications Asthma; Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Mundipharma Research
  • Most Recent Events

    • 15 Sep 2017 Results presented at the European Respiratory Society 2017.
    • 15 Sep 2017 New trial record
    • 09 Sep 2017 Results published in a Mundipharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top